Grant Pickering, Vaxcyte CEO

Vax­cyte to raise $500M from stock of­fer­ing for PhI­II study of pneu­mo­coc­cal vac­cine

Vax­cyte is set to raise $500 mil­lion via a stock sale to fund its work on a pneu­mo­coc­cal vac­cine it hopes can sup­plant Pfiz­er’s Pre­vnar …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA